ARIAD Receives Orphan Drug Designations For Its Investigational Pan BCR-ABL Inhibitor, AP24534, In Chronic Myeloid Leukemia

Posted by Jeff Daas on Mar 3rd, 2010 | no comments

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced that its investigational pan-BCR-ABL inhibitor, AP24534, has been granted orphan drug designation by both the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the U.S…
Read Full Article